National lupus organizations, and individuals with lupus and their families around the world, are rallying to protect access to new treatments of lupus.
Health Canada and European Medicines Agency Approves BENLYSTA™
July 13, 2011
Health Canada and European Regulators have approved BENLYSTA™ (belimumab), a new drug specific for the treatment of systemic lupus erythematosus. The announcement was made today by GlaxoSmithKline Inc. (GSK) and Human Genome Sciences (HGS) who are developing BENLYSTA™ under a co-development and co-commercialization agreement entered into in 2006. BENLYSTA™ is expected to become available to patients in Canada in September of this year.
Read more about BENLYSTA™ in Canada.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion, recommending marketing authorisation for BENLYSTA®.